Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stok Raporu

Piyasa değeri: US$2.3b

Ligand Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Ligand Pharmaceuticals CEO'su Todd Davis, Dec2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 6.22M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.5% maaş ve 89.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.42% ine doğrudan sahiptir ve bu hisseler $ 9.44M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2 yıl ve 15 yıldır.

Anahtar bilgiler

Todd Davis

İcra Kurulu Başkanı

US$6.2m

Toplam tazminat

CEO maaş yüzdesi10.5%
CEO görev süresi1.9yrs
CEO sahipliği0.4%
Yönetim ortalama görev süresi2yrs
Yönetim Kurulu ortalama görev süresi15yrs

Son yönetim güncellemeleri

Recent updates

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 24

Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Oct 31
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings

Ligand Pharmaceuticals: Solid Performer Performing Solidly

Jul 29

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Jul 18
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Jun 29
Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?

Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

May 23
Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%

Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio

Apr 30

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Dec 19
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar

Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

Jun 14
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

May 29
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

May 07
Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?

These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

Jan 26
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Ligand Pharmaceuticals: Struggling Along

Sep 25

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

CEO Tazminat Analizi

Todd Davis'un ücretlendirmesi Ligand Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

US$45m

Jun 30 2024n/an/a

US$42m

Mar 31 2024n/an/a

US$96m

Dec 31 2023US$6mUS$650k

US$54m

Sep 30 2023n/an/a

US$21m

Jun 30 2023n/an/a

US$41m

Mar 31 2023n/an/a

US$51m

Dec 31 2022US$6mUS$49k

-US$5m

Sep 30 2022n/an/a

US$23m

Jun 30 2022n/an/a

US$27m

Mar 31 2022n/an/a

US$45m

Dec 31 2021US$328kn/a

US$76m

Sep 30 2021n/an/a

US$68m

Jun 30 2021n/an/a

US$48m

Mar 31 2021n/an/a

US$39m

Dec 31 2020US$329kn/a

US$7m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$350kn/a

US$629m

Sep 30 2019n/an/a

US$594m

Jun 30 2019n/an/a

US$677m

Mar 31 2019n/an/a

US$764m

Dec 31 2018US$343kn/a

US$143m

Sep 30 2018n/an/a

US$179m

Jun 30 2018n/an/a

US$120m

Mar 31 2018n/an/a

US$53m

Dec 31 2017US$283kn/a

US$13m

Tazminat ve Piyasa: Todd 'ın toplam tazminatı ($USD 6.22M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.50M ).

Tazminat ve Kazançlar: Todd 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Todd Davis (63 yo)

1.9yrs

Görev süresi

US$6,216,518

Tazminat

Mr. Todd C. Davis, Ph.D. is a Director at NVN Liquidation Inc. He serves as an Independent Director of Channel Therapeutics Corporation (formerly known as Chromocell Therapeutics Corporation) since January...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Todd Davis
CEO & Director1.9yrsUS$6.22m0.42%
$ 9.4m
Octavio Espinoza
Chief Financial Officer2yrsUS$2.45m0.13%
$ 2.9m
Andrew Reardon
Chief Legal Officer & Secretary2yrsUS$2.34m0.12%
$ 2.7m
Paul Hadden
Senior Vice President of Investments & Business Developmentno dataVeri yokVeri yok
Michael Jeong
Head of Investor Relationsno dataVeri yokVeri yok
Todd Pettingill
Director of Corporate Developmentno dataVeri yokVeri yok
Keith Marschke
Senior Vice President of Biology & Scientific Affairs6.8yrsVeri yokVeri yok
Vincent Antle
Senior Vice President of Technical Operations & QA - Capitsol6.8yrsVeri yokVeri yok
Patrick Lucy
Senior VP & CBO Protein Expression Businessno dataVeri yokVeri yok
Karen Reeves
Senior VP of Investments & Head of Clinical Strategyless than a yearVeri yokVeri yok
Richard Baxter
Senior VP of Investment Operationless than a yearVeri yokVeri yok
Scott Plesha
CEO of Pelthos Therapeuticsless than a yearVeri yokVeri yok

2.0yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: LGND 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 2 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Todd Davis
CEO & Director17.7yrsUS$6.22m0.42%
$ 9.4m
John Kozarich
Independent Chairman21.7yrsUS$361.70k0.23%
$ 5.1m
John LaMattina
Independent Director13.8yrsUS$329.20k0.15%
$ 3.4m
Stephen Sabba
Independent Director16.3yrsUS$341.70k0.15%
$ 3.4m
Jason Aryeh
Independent Director18.2yrsUS$339.20k0.43%
$ 9.8m
Shalendar Bhasin
Scientific Advisorno dataVeri yokVeri yok
Jason Haas
Independent Director2.4yrsUS$346.70k0.022%
$ 494.1k
Nancy Gray
Independent Director7.3yrsUS$336.70k0.030%
$ 671.4k
Martine Zimmermann
Independent Director1.2yrsUS$467.87kVeri yok

15.0yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LGND 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15 yıldır).